Latest Breaking News On - Thomas baumert - Page 1 : vimarsana.com

Alentis Therapeutics: Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

Lixudebart (ALE.F02) is a first-in-class monoclonal antibody in clinical development for multi-organ fibrosis Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing

Luigi manentiSariette witteOpatrick wilsonThomas baumertSteven nathanProgram at inova fairfax hospitalUniversity of strasbourgDrug administrationFrench national institute of healthResearch insermOrphan drugIdiopathic pulmonary fibrosisChief medical officerMedical directorAdvanced lung diseaseTransplant program

Alentis Appoints Alberto Toso Chief Scientific Officer

BASEL, Switzerland, April 29, 2024 Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective immediately. Alberto joined Alentis in 2021 as Head of Oncology.

Thomas baumertSariette witteAlberto tosoRoberto iaconeOpatrick wilsonFrench national institute of healthResearch insermNature communicationsUniversity of strasbourgDepartment headInstitute of oncology research in bellinzonaAlentis therapeuticsChief scientific officerChief executive officerOncology researchFrench national institute

William Pao Joins Alentis Therapeutics as Independent Board Member

William Pao Joins Alentis Therapeutics as Independent Board Member
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Thomas baumertLuca santarelliRoberto iaconeWilliam paoGlobal product developmentYale universityVanderbilt universityUniversity of strasbourgResearch insermLeadership teamCorporate executive committeeFrench national institute of healthMemorial sloan kettering cancer centerPao joins alentis therapeuticsIndependent boardChief executive officer

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Baylor college of medicineUnited statesSan franciscoTexas medical centerRoberto iaconeThomas baumertWilliam blairStefan klotterRizwan veljiSariette witteOpatrick wilsonMcgill universityResearch insermFrench national institute of healthNorthwestern universityUniversity of strasbourg

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business

Velji brings more than 20 years of experience in biotech financial servicesBASEL, Switzerland (BUSINESS WIRE) Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today announced that Rizwan Velji has been appointe.

San franciscoUnited statesBaylor college of medicineTexas medical centerOpatrick wilsonThomas baumertRizwan veljiWilliam blairRoberto iaconeSariette witteNorthwestern universityFrench national institute of healthResearch insermMcgill universityUniversity of strasbourgAlentis therapeutics